Yan Chen
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research 45
- Cancer, Hypoxia, and Metabolism 32
- MicroRNA in disease regulation 21
- Molecular Biology top 1%
- RNA modifications and cancer 34
- Epigenetics and DNA Methylation 31
- Ubiquitin and proteasome pathways 25
- Immunology top 1%
- Immune Cell Function and Interaction 25
- interferon and immune responses 19
- Hepatology top 2%
- Oncology top 2%
- Journals
- Frontiers in Oncology (8 papers)Frontiers in Immunology (7 papers)Cancer Research (6 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Yan Chen
365 papers receiving 8.9k citations
Hit Papers
Peers
Comparison fields: 5 of 161
- Cancer Research 2.0k
- Molecular Biology 5.1k
- Immunology 1.6k
- Hepatology 468
- Oncology 1.3k
Countries citing papers authored by Yan Chen
This map shows the geographic impact of Yan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Chen more than expected).
Fields of papers citing papers by Yan Chen
This network shows the impact of papers produced by Yan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Chen. The network helps show where Yan Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yan Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 9 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 3 | |
| 8 | 2024 | 4 | |
| 9 | 2023 | 2 | |
| 10 | 2023 | 11 | |
| 11 | 2023 | 25 | |
| 12 | 2023 | 4 | |
| 13 | 2022 | 25 | |
| 14 | 2022 | 11 | |
| 15 | 2022 | 12 | |
| 16 | 2021 | 31 | |
| 17 | 2020 | 45 | |
| 18 | Study on the correlation between CD4~+ cytotoxic T and course of primary hepatocellular carcinoma | 2013 | 1 |
| 19 | 2012 | 276 | |
| 20 | 2011 | 48 |
About Yan Chen
Yan Chen is a scholar working on Cancer Research, Immunology, Molecular Biology, Virology and Oncology, having authored 379 papers that have together received 8.9k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (45 papers), RNA modifications and cancer (34 papers), Cancer, Hypoxia, and Metabolism (32 papers), Epigenetics and DNA Methylation (31 papers), Ubiquitin and proteasome pathways (25 papers), Immune Cell Function and Interaction (25 papers), MicroRNA in disease regulation (21 papers) and interferon and immune responses (19 papers). The work is most often cited by research in Cancer Research (2.0k citations), Molecular Biology (5.1k citations), Immunology (1.6k citations), Hepatology (468 citations) and Oncology (1.3k citations). Yan Chen has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Jin Ye, Hua Huang, Michael Gale, Fang Sun, David M. Owen, Weibo Luo, Weiping Li, Yingfei Wang, James L. Manley and Roland Tacke. Their work appears in journals such as Frontiers in Oncology, Frontiers in Immunology, Cancer Research, Biochemical and Biophysical Research Communications and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.